Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Growth in Short Interest

Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Rating) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 18,010,000 shares, a growth of 5.4% from the February 13th total of 17,080,000 shares. Approximately 15.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is presently 16.2 days.

Lyell Immunopharma Stock Down 2.7 %

Shares of Lyell Immunopharma stock opened at $2.13 on Friday. The company has a market capitalization of $531.67 million, a P/E ratio of -2.88 and a beta of -1.68. Lyell Immunopharma has a 52-week low of $1.88 and a 52-week high of $8.74. The company has a 50 day moving average of $2.73 and a 200 day moving average of $4.49.

Lyell Immunopharma (NASDAQ:LYEL – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.28. Lyell Immunopharma had a negative net margin of 216.24% and a negative return on equity of 21.53%. The business had revenue of $48.39 million during the quarter, compared to the consensus estimate of $2.85 million. As a group, research analysts anticipate that Lyell Immunopharma will post -1.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

LYEL has been the topic of a number of analyst reports. Morgan Stanley lowered their target price on shares of Lyell Immunopharma from $7.00 to $4.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 24th. HC Wainwright decreased their target price on shares of Lyell Immunopharma from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, March 2nd.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Advisor Group Holdings Inc. boosted its holdings in Lyell Immunopharma by 3,125.3% in the fourth quarter. Advisor Group Holdings Inc. now owns 7,902 shares of the company’s stock worth $27,000 after purchasing an additional 7,657 shares during the period. Mariner LLC bought a new stake in Lyell Immunopharma in the fourth quarter worth about $35,000. Royal Bank of Canada raised its holdings in Lyell Immunopharma by 76.1% during the 1st quarter. Royal Bank of Canada now owns 9,114 shares of the company’s stock worth $46,000 after buying an additional 3,940 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in Lyell Immunopharma during the 1st quarter worth about $50,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Lyell Immunopharma during the 1st quarter valued at about $52,000. Hedge funds and other institutional investors own 45.04% of the company’s stock.

About Lyell Immunopharma

(Get Rating)

Lyell Immunopharma, Inc, a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.